Search
Acemetacin
go.drugbank.com/drugs/DB13783ApprovedInvestigationalMerck and Company in Germany as an attempt to provide a safer drug but other than the amelioration on the gastrointestinal effects, the metabolism of acetamicin led to the formation of indomethacin and … [A31352] In clinical trials, acemetacin exhibits a better gastric tolerability compared to its active metabolite indometacin.[T50] It was developed by E.
Categories: Acetic Acid Derivatives and Related Substances, Antiinflammatory and Antirheumatic ProductsProducts: AZEAT 30MG, AZEAT 60MGStage IV Hodgkin's Disease
go.drugbank.com/conditions/DBCOND0111729Drugs: ProcarbazineSynonyms: Hodgkin's disease, unspecified site, extranodal and solid organ sitesSirolimus
go.drugbank.com/drugs/DB00877ApprovedInvestigational[A242372] The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with … [A242372] In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids.
Categories: Sirolimus and Prodrugs, Antineoplastic and Immunomodulating AgentsMenadione
go.drugbank.com/drugs/DB00170ApprovedNutraceuticalA synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.
Mixtures: LIBAVIT-K 20 MG AMPUL, 5 ADETCategories: Blood and Blood Forming Organs, Diet, Food, and NutritionIxazomib
go.drugbank.com/drugs/DB09570ApprovedInvestigational[A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016. … [A7948] More than 99% of the drug compound is the R-enantiomer.[A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US.
Categories: Antineoplastic and Immunomodulating AgentsEprosartan
go.drugbank.com/drugs/DB00876ApprovedInvestigationalBy preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced. … Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system.
Mixtures: TEVETEN PLUS 600MG/12.5MGCategories: Angiotensin II receptor blockers (ARBs) and diuretics, eprosartan and diureticsTechnetium Tc-99m succimer
go.drugbank.com/drugs/DB09436ApprovedTechnetium Tc-99m (<sup>99m</sup>Tc) succimer, also known as technetium Tc-99m dimercaptosuccinic acid (DMSA),[A245643] is a radioactive diagnostic agent used to evaluate functional renal tissue and tubular … It works by binding to the cortical region of the kidneys. Technetium Tc-99m succimer is used with gamma scintigraphy or single-photon emission computed tomography (SPECT).
Categories: Indicators and Reagents, Compounds used in a research, industrial, or household settingVoxelotor
go.drugbank.com/drugs/DB14975ApprovedSickle cell disease can lead to excruciating pain, stroke, infection, and various other complications arising from the blockage of blood vessels. … [L10403] It was developed by Global Blood Therapeutics, Inc.
Categories: Blood and Blood Forming OrgansBlinatumomab
go.drugbank.com/drugs/DB09052ApprovedInvestigationalBlinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through … It was first approved by the FDA in December 2014 for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsCatumaxomab
go.drugbank.com/drugs/DB06607ApprovedWithdrawnCatumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. … Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites [L1122].
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating Agents